You’re probably seeing it in your practice already: patients asking about Ozempic, Wegovy, or ‘those weight loss shots.’ Maybe they’ve gained 40 pounds on Seroquel or Abilify. Maybe they’re battling depression and obesity, and traditional psychiatry isn’t addressing the metabolic piece. Or maybe you’re just hearing the buzz and wondering if this is a legitimate path to grow your practice.

Here’s the short answer: Yes, psychiatrists and psychiatric nurse practitioners can—and increasingly should—consider offering GLP-1 weight loss treatment as part of integrated care. Not because it’s trendy, but because the evidence supports it, your patients need it, and it represents a significant practice growth opportunity in 2026 and beyond.

Let me explain why this makes clinical and business sense, what you need to know about doing it safely, and how it fits into the bigger picture of modern psychiatric practice.

Why Weight Loss Is Becoming Part of Psychiatric Care

The Clinical Reality: Obesity and mental health are deeply interconnected. About 40% of adults with depression or anxiety also have obesity. Many psychiatric medications—particularly atypical antipsychotics, mood stabilizers, and some antidepressants—cause significant weight gain that patients hate. This weight gain often leads to medication non-adherence, which tanks treatment outcomes.

Traditional psychiatry’s answer? ‘Talk to your primary care doctor about diet and exercise.’ But let’s be honest—that rarely works. PCPs are overwhelmed, patients feel dismissed, and the weight stays on.

Enter GLP-1 medications. Originally developed for diabetes, drugs like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) produce 10-15% body weight loss in clinical trials—dramatically better than anything we’ve had before. They work by mimicking gut hormones that regulate appetite and blood sugar, making patients feel fuller longer and reducing food cravings.

Here’s what matters for psychiatrists: mounting evidence shows GLP-1s are psychiatrically safe and may even improve mental health outcomes. Studies indicate they don’t increase depression or suicidality—in fact, patients often report improved mood and quality of life as they lose weight. Research has even shown potential benefits in addiction (reduced alcohol and substance cravings) and improved cognitive function.

As Dr. Alex Spencer, a metabolic psychiatrist, writes: ‘These medications affect brain reward pathways, neurotransmitter function, and inflammatory processes—all relevant to psychiatric practice. The systems governing metabolism and mental health are inseparable. Treating metabolic illness can improve mental health, and vice versa.’

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

The Market Opportunity: Massive Demand, Limited Supply

Let’s talk numbers, because this isn’t just about better patient care—it’s about practice sustainability.

Patient Demand Is Exploding:

• An estimated 18 million Americans (7% of adults) were using GLP-1 drugs for weight loss by 2024
• Survey data from 2025-26 shows 8-10% of Americans currently use GLP-1s, with another 30-35% expressing interest in using them
• Google searches for ‘how to get Ozempic for weight loss’ generated over 100,000 monthly clicks in 2024
• The weight-loss telehealth market hit $6.9 billion in 2023, growing 8% annually

Provider Supply Is Constrained:

• Traditional bariatricians and endocrinologists can’t meet demand
• Many PCPs are hesitant to prescribe GLP-1s (unfamiliar with dosing, worried about side effects, no time for follow-up)
• Telehealth startups have flooded in, but many offer cookie-cutter care without addressing the behavioral health component

This creates a sweet spot for psychiatric providers. You already manage complex medication regimens. You understand behavioral change. You have patients who desperately need weight management but aren’t getting it elsewhere.

How This Grows Your Practice: The Economics

Let’s get specific about revenue potential, because that’s what pays your bills.

The Patient Economics:A typical weight-loss patient on GLP-1 therapy represents approximately $600-800 in annual service revenue (not counting the medication itself, which patients get through pharmacy). This breaks down to:

• Initial comprehensive evaluation: $150-200
• Monthly follow-up visits: $75-100 × 10-12 visits = $750-1,200

Many patients stay on treatment for 12-18 months or longer, so lifetime value can exceed $1,000 per patient in professional fees alone.

Patient Acquisition Advantages:Unlike traditional psychiatric patients who often find you through insurance directories or referrals, weight-loss patients are actively searching online. Top search queries include:

• ‘GLP-1 prescription online’
• ‘Wegovy doctor near me’
• ‘psychiatric medication weight gain help’
• ‘Ozempic for weight loss [your city]’

This means your SEO and digital marketing can directly drive patient volume—no need to wait months building referral relationships.

The Cash-Pay Reality:Here’s an important consideration: many weight-loss patients are cash-pay because:

• Insurance coverage for obesity medications varies wildly by state and plan
• Some patients prefer keeping weight treatment off their insurance records
• The convenience of telehealth and direct payment appeals to busy professionals

This creates a self-pay revenue stream that isn’t subject to insurance reimbursement hassles or prior authorizations. You set your fee, patients pay it, everyone’s clear on expectations.

Compared to Traditional Patient Acquisition:Building a traditional psychiatric practice through marketing typically costs $200-500+ per patient when you factor in:

• SEO investment (6-12 months before meaningful results)
• Google Ads for mental health keywords ($15-40+ per click)
• Directory listings (Psychology Today, Zocdoc monthly fees plus per-booking charges)
• Staff time qualifying leads and managing no-shows
• Failed campaigns and wasted ad spend

Weight-loss services tend to have faster patient acquisition because:

1. Search volume is higher (people proactively looking)
2. Decision cycle is shorter (patients want to start quickly)
3. Word-of-mouth spreads faster (visible results)
4. Less stigma than mental health treatment (easier to refer friends)

State-by-State Considerations: Where This Works Best

Your ability to offer GLP-1 treatment depends significantly on where you practice. Here’s the breakdown for our priority states:

California: Excellent opportunity. As of 2026, experienced psychiatric NPs can practice independently (full practice authority after 3 years). California’s Medicaid (Medi-Cal) covers GLP-1 obesity medications, leading to $1.4 billion in spending in 2024—massive patient access. Competition is fierce (lots of telehealth startups), but the market is huge. Obesity prevalence ~28%, but that’s millions of people in absolute numbers.

Texas: Strong demand (35%+ obesity rate), but NPs need physician supervision. Good news: telehealth is widely accepted, and Texas law allows establishing care remotely. Challenge: Texas Medicaid only has partial GLP-1 coverage, so many patients will be cash-pay or need help with manufacturer programs. Large rural population underserved for specialty care—telehealth shines here.

Florida: Interesting regulatory environment. Out-of-state providers can register to treat Florida patients via telehealth without full licensure—opens the market wide. Florida has wealthy retirees and cosmetically-focused populations (Miami, etc.) willing to pay cash. However, Florida Medicaid does not cover obesity GLP-1s, limiting low-income patient access. High obesity rates and aesthetic interest create opportunity.

New York: Full NP practice authority after 3,600 hours. Huge population, high demand, especially in NYC metro. Downside: New York Medicaid excludes obesity medication coverage—focus on commercial insurance and cash patients. Strong academic/hospital competition, but also sophisticated consumers who value specialized expertise. A psychiatrist offering integrated mental health + weight management could differentiate well.

Pennsylvania: PA is lagging on NP independence (still requires physician collaboration), but has a major advantage: Pennsylvania Medicaid covers GLP-1 obesity drugs and spent $298M in 2024, second only to California. This means your practice can serve insured lower-income patients, not just cash-pay. High obesity rates (33-35%), large rural areas needing telehealth. If you can navigate the NP supervision requirement, this is a growth-friendly state.

Illinois: Full practice authority for experienced NPs (after 4,000 hours + training). Telehealth parity in insurance. Challenge: Illinois Medicaid currently does not cover obesity medications specifically, though legislation is pending. Focus on employer-insured and cash patients. Chicago and suburbs have high demand; diverse population means culturally tailored care can capture market share.

Federal Controlled Substance Note: If you were thinking of combining GLP-1s with traditional appetite suppressants like phentermine (a Schedule IV controlled substance), be aware: the DEA’s COVID-era telehealth prescribing flexibility expires December 31, 2025. After that, new patients will likely require one in-person visit before you can prescribe controlled substances via telehealth. However, GLP-1 medications are non-controlled, so you can prescribe them via telehealth without this restriction—making them ideal for remote care.

What You Need to Know Clinically

Scope of Practice: You’re already prescribing complex psychotropics. GLP-1s are actually simpler in many ways—subcutaneous injection, predictable titration schedule, manageable side effect profile (mostly GI: nausea, occasional vomiting). The key is proper patient selection and monitoring.

Who’s a Good Candidate?

• BMI ≥30, or ≥27 with weight-related comorbidity
• Motivated to make lifestyle changes (these aren’t magic bullets)
• Can tolerate weekly injections
• No contraindications (personal/family history of medullary thyroid cancer, MEN2 syndrome)
• Ideally, already engaged in psychiatric treatment (you know their baseline mental state)

The Integration Sweet Spot:You’re not trying to become a bariatric specialist. Think of this as metabolic psychiatry—addressing the whole person. Your ideal patients are:

• People on antipsychotics who’ve gained significant weight
• Depression/anxiety patients with obesity and food cravings
• Binge eating disorder (GLP-1s show promise here)
• Patients struggling with medication compliance because of weight gain
• Those asking about weight who currently get no help from traditional psych

Monitoring Protocol:

• Baseline: weight, BMI, A1C, lipids, basic metabolic panel
• Start low dose, titrate monthly based on tolerance and response
• Monthly check-ins for first 3-4 months (can be 15-minute telehealth)
• Monitor for side effects (nausea management is key early on)
• Screen for psychiatric symptoms (depression, suicidality—though evidence shows no increased risk)
• Combine with behavioral support (even brief motivational interviewing makes a difference)

Realistic Expectations:Clinical trials show 15% average weight loss, but real-world outcomes are more modest: patients lose 7-12% of body weight on average after one year. About half of patients discontinue within a year (side effects, cost, reaching plateau). Setting proper expectations upfront—and providing support to maximize adherence—is crucial.

Dr. Spencer’s approach is instructive: ‘I prescribe these medications regularly, but I always emphasize that they work best as part of comprehensive care. That means addressing nutrition, movement, sleep, and stress—not just depending on medication. I also start at lower doses and increase more gradually than typical weight clinics, which reduces side effects and improves long-term adherence.’

Marketing Your Weight Loss Services: What Actually Works

Once you decide to offer GLP-1 treatment, you need patients to find you. Here’s what works based on actual data from weight-loss practices:

1. Content Marketing and SEO (Highest ROI)Content marketing generates 3× more leads at 62% lower cost than paid ads alone. Translation: write blog posts answering the questions your patients are Googling:

• ‘Can a psychiatrist help with weight loss?’
• ‘GLP-1 medications for antipsychotic weight gain’
• ‘Wegovy vs Ozempic: what’s the difference?’
• ‘Safe weight loss for depression patients’
• ‘[Your city] psychiatric weight management’

These posts rank in Google for months or years, bringing steady patient flow at zero ongoing cost. One well-written article can generate dozens of patient inquiries over its lifetime.

2. Email Marketing (Exceptional ROI)Build an email list through your website (‘Free guide: Managing medication-related weight gain’). Email marketing delivers an average $42 return per $1 spent—higher than any other digital channel. Use it to:

• Nurture prospects who aren’t ready to book yet
• Re-engage past patients who’ve lapsed
• Share success stories (with permission)
• Announce insurance coverage changes or new treatment options

3. Paid Advertising (Use Strategically)Google Ads for GLP-1 keywords are expensive (big companies spent millions fighting for ‘Ozempic’ clicks). Instead:

• Target long-tail, less competitive phrases: ‘psychiatric weight loss doctor [city],’ ‘help with Abilify weight gain’
• Use retargeting to stay in front of website visitors
• Set strict budgets and track cost per booked appointment
• Aim for 5:1 ROI minimum ($1,000 spent = $5,000 in patient revenue)

4. Leverage Social ProofWeight loss is uniquely visual. With proper patient consent and HIPAA compliance:

• Share de-identified before/after stories (focus on health improvements, not just appearance)
• Collect video testimonials about improved energy, mood, medication tolerance
• Post regularly about the science behind GLP-1s (education builds trust)
• Highlight your dual expertise: ‘I’m a psychiatrist who understands both mental health and the metabolic challenges of psychiatric medications’

5. Define Your NicheDon’t try to be everything to everyone. Successful practices get specific:

• ‘Weight management for patients on psychiatric medications’
• ‘Integrated mental health and metabolic care’
• ‘Women over 40 struggling with medication weight gain and mood’

Specific messaging attracts better-fit patients and improves conversion rates.

6. Track Your MetricsMeasure what matters:

• Cost per lead (website visitor who contacts you)
• Lead-to-patient conversion rate (what % actually book and show up?)
• Patient lifetime value (average revenue per patient over their treatment course)
• Return on marketing investment (revenue generated ÷ marketing spend)

If your average patient is worth $800 in service fees, you can afford to spend $150-200 to acquire them and still maintain healthy margins. Use these numbers to guide where you invest marketing dollars.

Compliance Note: Keep all marketing honest and evidence-based. Avoid ‘guaranteed results’ or dramatic before/after photos that could be misleading. Focus on your qualifications, the science, and realistic patient experiences. State boards and the FTC take false weight-loss claims seriously.

What Patients Are Actually Searching For

Understanding patient search behavior helps you show up where they’re looking:

Top Search Queries:

• ‘How to get Ozempic for weight loss’ (~113,000+ searches/month)
• ‘Ozempic prescription online’
• ‘Wegovy near me’
• ‘GLP-1 weight loss doctor’
• ‘Compounded semaglutide’ (for patients seeking lower-cost options)
• ‘[State] Medicaid Wegovy coverage’

What They Care About:

• Speed and convenience: ‘Can I start this week?’ ‘Do you do telehealth?’
• Cost transparency: ‘How much per month?’ ‘Does insurance cover it?’
• Safety: ‘Is this safe with my antidepressants?’
• Privacy: Many patients want discretion (stigma around both weight and mental health)
• Results: ‘What kind of weight loss can I expect?’

Different Patient Personas:Marketing research identifies several GLP-1 patient types:

• The Busy Parent: Overwhelmed, looking for convenient solution, searches ‘easy weight loss program’
• The Silent Sufferer: Ashamed of weight, prefers telehealth for privacy, avoids in-person clinics
• The Health Optimizer: Wants to lose weight for health reasons (labs improving, energy up), not just appearance
• The Frustrated Dieter: Tried everything, skeptical but hopeful, needs education and trust-building

Your messaging should speak to these different motivations. As a psychiatrist, you’re uniquely positioned to address the emotional and behavioral components other weight-loss providers ignore.

The Business Model: How to Structure This

Three Approaches:

1. Add-On Service (Easiest Start):Offer GLP-1 management to your existing psychiatric patients who need it. No new marketing required—just let current patients know you now provide this. Start with 5-10 patients to refine your workflow, then scale.

Revenue impact: If you have 100 active psychiatric patients and 20% are interested in weight management, that’s 20 × $600 = $12,000 additional annual revenue with minimal overhead.

2. Dedicated Weight Management Track:Create a separate service line for weight management, marketed specifically to that population. You’ll attract new patients who may not need psychiatric care but want GLP-1 treatment from a provider who understands behavioral health.

Revenue impact: If you build a panel of 50 weight-loss patients (achievable in 6-12 months with consistent marketing), that’s 50 × $700 = $35,000 annual revenue, mostly cash-pay.

3. Hybrid Integrated Practice:Position yourself as a ‘metabolic psychiatrist’—someone who treats mental health and metabolic health as interconnected. This is the most differentiated approach and can command premium fees.

Revenue impact: Higher patient lifetime value (treating both conditions simultaneously), stronger patient retention, premium positioning allows $150-200+ per visit.

Platform Partnership Option:Alternatively, join a telehealth platform like Klarity Health that handles patient acquisition, credentialing, and infrastructure. You pay a fee per appointment but get pre-qualified patients already interested in your services, with zero marketing spend or monthly overhead. This removes the risk of investing thousands in marketing with uncertain results—you only pay when you see patients.

For providers starting out or those who want to focus on clinical care rather than business operations, platforms that use a pay-per-appointment model can deliver immediate patient flow while you build reputation. The tradeoff is lower per-patient margin but guaranteed ROI and zero wasted ad spend.

Common Objections (And Responses)

‘This isn’t really psychiatry.’Response: Psychiatry is evolving. We’ve moved beyond the couch to embrace psychopharmacology, TMS, ketamine, and now metabolic interventions. If a medication you prescribed caused 40-pound weight gain that’s destroying your patient’s life, is it really outside your scope to help fix it? The brain and body aren’t separate—metabolic psychiatry acknowledges that.

‘I don’t have time to add another service.’Response: GLP-1 management is actually less time-intensive than therapy or complex med management. After initial evaluation, follow-ups are brief (15 minutes). Many providers do them via telehealth between other appointments. And with the revenue potential, you can afford to hire support staff or cut back other activities.

‘What if I don’t know enough about obesity medicine?’Response: You don’t need to become a bariatrician. Focus on the subset you’re comfortable with—medication-induced weight gain, patients with psychiatric comorbidities, those struggling with emotional eating. Plenty of continuing education is available (Obesity Medicine Association offers CME, online courses on GLP-1 prescribing). Start small, learn as you go, consult with colleagues when needed.

‘Insurance won’t cover it.’Response: Coverage is improving rapidly. Many employer plans now cover GLP-1s (52% of large employers in 2024). Several state Medicaid programs cover obesity treatment (California, Pennsylvania, plus ~12 others). For patients without coverage, manufacturer savings programs, compounded semaglutide, or self-pay are options. Part of your value is helping patients navigate access.

‘Won’t telehealth startups undercut me on price?’Response: Possibly on cost, but not on value. Big telehealth mills offer transactional care—quick prescription, minimal follow-up, no behavioral support. You offer expertise in the mind-body connection, close monitoring, and integration with psychiatric treatment. Patients willing to pay for quality will choose you. Plus, many are frustrated with impersonal online-only services and seeking a real doctor relationship.

The Bottom Line: Is This Right for Your Practice?

Adding GLP-1 weight loss services makes sense if:

• You’re seeing patients struggle with medication-induced weight gain
• You want to grow revenue without expanding hours dramatically
• You’re comfortable with telehealth and simple injection medications
• You have or can build an online presence to attract patients
• Your state regulations support it (check NP independence, telehealth rules, Medicaid coverage)

It’s probably not right if:

• You’re nearing retirement and don’t want to learn new systems
• Your practice is maxed out capacity with a waitlist for traditional services
• You’re philosophically opposed to weight-focused medical care
• Your state’s regulatory environment is prohibitively complex

Getting Started: Next Steps

If you’re interested in exploring this:

1. Verify your state’s requirements (licensure, telehealth rules, scope of practice for your credential)

2. Get educated: Take a CME course on obesity pharmacotherapy and GLP-1s specifically. The Obesity Medicine Association, American Board of Obesity Medicine, and various online platforms offer training.

3. Start with existing patients: Identify 5-10 current patients who could benefit. Offer the service, work out your workflow, refine your documentation templates.

4. Build your marketing foundation:

• Update your website to mention weight management services
• Write 2-3 blog posts targeting relevant keywords
• Create a simple email capture for prospects
• Optimize your Google My Business listing

5. Consider platform partnership: If marketing isn’t your strength or you want immediate patient flow, explore joining a network that brings patients to you. Platforms like Klarity Health offer pay-per-appointment models—you avoid upfront marketing costs and get matched with patients already seeking services. For many providers, this is the lowest-risk way to test the waters.

6. Track and adjust: Measure patient volume, satisfaction, clinical outcomes, and revenue. If it’s working, scale up. If not, pivot.

The Bigger Picture

The GLP-1 weight loss trend represents a fundamental shift in how we treat obesity—from ‘just eat less and exercise more’ to recognizing it as a chronic disease requiring medical intervention. With roughly one-third of American adults interested in these medications, demand will remain strong for years.

As a psychiatric provider, you have unique advantages in this space:

• You understand medication side effects and interactions
• You recognize the behavioral and emotional components of eating
• You’re trained in motivational interviewing and behavior change
• You already have patients who need this service
• You can offer integrated, holistic care that purely weight-focused clinics can’t

The question isn’t whether there’s opportunity here—there clearly is. The question is whether it fits your practice goals and patient population. For many psychiatrists and psychiatric NPs, the answer is yes.

Frequently Asked Questions

Can psychiatric nurse practitioners prescribe GLP-1 medications?Yes, in most states. PMHNPs with prescribing authority can prescribe GLP-1s (they’re non-controlled substances). However, your state’s scope-of-practice rules matter. In full-practice states (California, New York, Illinois after experience), NPs can do this independently. In restricted states (Texas, Pennsylvania), you’ll need physician collaboration. Check your state’s NP practice act.

Do I need special certification to prescribe weight-loss medications?No specific certification is required, but additional training is wise. CME courses on obesity pharmacotherapy, GLP-1 mechanisms, and weight management best practices will strengthen your competence and confidence. Some providers pursue obesity medicine board certification (ABOM), but it’s not mandatory.

How do I handle insurance coverage and prior authorizations?Coverage varies widely. Many commercial plans cover GLP-1s for obesity (often with prior auth requiring BMI ≥30 or ≥27 with comorbidities). State Medicaid programs differ—California, Pennsylvania, and about 12 other states cover obesity indications; many don’t. Medicare currently excludes obesity drugs (changing in 2027 possibly). Your office staff can handle prior auths, or you can work with a pharmacy benefits specialist. For denied cases, manufacturer savings cards or compounded alternatives may help.

What about patients already on psychiatric medications—are there interactions?GLP-1s have minimal drug interactions because they’re peptides, not metabolized by liver enzymes. They can slow gastric emptying, potentially affecting absorption of oral meds, but clinically this is rarely significant. Monitor patients as you would normally. Be alert for any psychiatric symptom changes, though evidence suggests GLP-1s don’t worsen depression or anxiety.

Is it ethical to profit from weight loss treatment, given societal pressures on body image?This is a thoughtful question. The ethical approach is to offer weight management for health reasons—reducing diabetes risk, improving mobility, alleviating medication side effects—not purely cosmetic. Screen for eating disorders and unrealistic expectations. Emphasize sustainable, medically supervised treatment. Done right, you’re empowering patients to reclaim their health, not exploiting insecurities.

How much time does weight-loss management add to my schedule?Initial comprehensive evaluation: 30-45 minutes (taking history, reviewing labs, discussing options). Follow-up visits: 15-20 minutes monthly for the first few months, then every 6-8 weeks once stable. Many providers do follow-ups via telehealth between other appointments. It’s actually less time-intensive than traditional psychotherapy.

What if a patient experiences severe side effects or doesn’t lose weight?For side effects (usually nausea), dose titration and symptomatic management usually help. If intolerable, discontinue and try an alternative (different GLP-1, older medication like phentermine, or non-medication approaches). For non-responders (~10-20% don’t lose significant weight), reassess: Are they adherent? Realistic expectations set? Consider adding behavioral support or evaluating for other causes (hypothyroidism, etc.). Part of informed consent is acknowledging not everyone responds equally.

Can I combine GLP-1s with other weight-loss medications?Potentially. Some providers combine GLP-1s with metformin (for metabolic benefit), phentermine (appetite suppressant), or naltrexone/bupropion (Contrave). However, remember the DEA telehealth rules for controlled substances (phentermine requires in-person visit post-2025 for new patients). If combining meds, monitor closely and ideally have additional training on polypharmacy in obesity.

What’s the difference between Ozempic, Wegovy, Mounjaro, and Zepbound?

• Ozempic (semaglutide): FDA-approved for type 2 diabetes; often prescribed off-label for weight loss at 1-2mg doses.
• Wegovy (semaglutide): Same drug as Ozempic, but FDA-approved specifically for obesity at higher dose (2.4mg).
• Mounjaro (tirzepatide): Approved for diabetes; dual GLP-1/GIP agonist, often more effective for weight loss than semaglutide.
• Zepbound (tirzepatide): Same drug as Mounjaro, FDA-approved for obesity.

Clinically: Tirzepatide (Mounjaro/Zepbound) tends to produce more weight loss than semaglutide but costs more and may have more GI side effects. Insurance coverage varies by brand.

How do I market weight loss services without attracting the wrong patient type?Be specific in your messaging: ‘Weight management for patients on psychiatric medications’ or ‘Integrated mental health and metabolic care’ rather than generic ‘Lose 30 pounds fast!’ This self-selects patients looking for comprehensive, medically supervised care. Require an initial consultation where you assess fit—patients seeking quick cosmetic fixes or those with untreated eating disorders may not be appropriate for your practice.

What happens when patients reach their goal weight or want to stop medication?Clinical data shows most patients regain weight after stopping GLP-1s, though usually not all of it. Best practice is to discuss this upfront—these medications work best as long-term management, much like antidepressants for depression. Some patients do pause or reduce dose after significant loss, combined with maintained lifestyle changes. Ongoing follow-up (even if less frequent) helps monitor for regain and restart if needed.

Ready to explore this opportunity further? Whether you’re thinking about adding weight management to your existing practice or want to build a dedicated metabolic psychiatry service, the fundamentals are clear: patient demand is enormous, the clinical evidence supports psychiatric providers offering this care, and the revenue potential is significant.

If you’re interested in joining a platform that handles patient acquisition and infrastructure so you can focus purely on clinical care, explore Klarity Health’s provider network. We connect licensed psychiatrists and psychiatric NPs with patients seeking GLP-1 weight management and integrated mental health care—you set your schedule, we bring qualified patients to you, and you only pay per appointment with zero upfront marketing costs.

The future of psychiatry is holistic—treating the whole person, mind and body. GLP-1 weight loss management is one more tool to help your patients thrive.

Executive Summary: Top 5 Citations (Weight Loss/GLP-1 Practice Growth)

1. Dr. Alex Spencer, Metabolic Psychiatrist – ‘Should Psychiatrists Prescribe GLP-1 Medications? An Evidence-Based Perspective’ (drlewis.com, January 4, 2026)
   Clinical perspective from practicing psychiatrist on integrating GLP-1s into psychiatric care, citing safety data and metabolic-mental health connection.
   https://drlewis.com/glp-1-medications-psychiatry/

2. Bask Health – ‘GLP-1 Weight Loss Persona Marketing: Understanding Patient Motivations’ (bask.health, January 2, 2026)
   Industry analysis of patient search behavior and demand patterns; reports ~8-10% current US GLP-1 usage with 30-35% expressing interest.
   https://bask.health/blog/glp-1-weight-loss-persona-marketing

3. Marketdata LLC – ‘$6.9 Billion Weight Loss Telehealth Market Grows, But Gets Crowded’ (blog.marketresearch.com, April 16, 2024)
   Market research on telehealth weight-loss industry size, growth rates, and patient spending patterns; cites 7% of US adults (~18 million) using GLP-1s for weight loss.
   https://blog.marketresearch.com/6.9-billion-weight-loss-telehealth-market-grows-but-gets-crowded

4. Real Chemistry State Analysis – ‘State-by-State Medicaid Coverage of GLP-1 Weight Loss Medications’ (realchemistry.com, December 15, 2024, updated January 2, 2025)
   Detailed breakdown of which state Medicaid programs cover obesity GLP-1 drugs and spending data; shows California ($1.4B) and Pennsylvania ($298M) leading in coverage.
   https://www.realchemistry.com/state-by-state-analysis-of-medicaid-coverage-for-glp-1-weight-loss

5. JAMA Network Open – Klein et al., ‘Direct-to-Consumer Advertising of GLP-1 Receptor Agonists and Trends in Health Care Use’ (PMC article PMC12579337, October 31, 2025)
   Peer-reviewed study analyzing Google Ads spending and search behavior for GLP-1 medications; documents over $7.5M spent on Ozempic-related keywords and top search queries driving patient interest.
   https://pmc.ncbi.nlm.nih.gov/articles/PMC12579337/

Source:

• https://bask.health/blog/glp-1-weight-loss-persona-marketing#:~:text=movement%20that%20changes%20healthcare
• https://blog.marketresearch.com/6.9-billion-weight-loss-telehealth-market-grows-but-gets-crowded#:~:text=consumers%20like%20the%20convenience
• https://drlewis.com/glp-1-medications-psychiatry/#:~:text=I%20want%20to%20address%20a,1%20receptor%20agonist%20medications
• https://drlewis.com/glp-1-medications-psychiatry/#:~:text=%2A%20GLP,1s%20as%20part%20of%20integrated
• https://drlewis.com/glp-1-medications-psychiatry/#:~:text=neurotransmitter%20function%20,psychiatric%20care
• https://drlewis.com/glp-1-medications-psychiatry/#:~:text=Traditionally%2C%20psychiatrists%20prescribe%20psychiatric%20medications,primarily%20indicated%20for%20metabolic%20conditions
• https://blog.marketresearch.com/6.9-billion-weight-loss-telehealth-market-grows-but-gets-crowded#:~:text=Top%20Things%20to%20Know%20About,Weight%20Loss%20Telehealth%20Services
• https://www.tactionsoft.com/blog/glp-1-virtual-clinic/#:~:text=Major%20Players%3A%20Digital%20health%20companies,and%20independent%20provider%20practices
• https://www.tactionsoft.com/blog/glp-1-virtual-clinic/#:~:text=,independent%20provider%20practices
• https://www.statnews.com/2025/11/18/telehealth-pharma-glp1-partnerships-increase-drug-access-boost-sales/#:~:text=Patients%20searching%20for%20those%20deals,that%20partner%20with%20Novo%20Nordisk